Cellosaurus logo
expasy logo

Cellosaurus T98G (CVCL_0556)

[Text version]
Cell line name T98G
Synonyms T 98 G; T-98G; T98 G; T98-G
Accession CVCL_0556
Resource Identification Initiative To cite this cell line use: T98G (RRID:CVCL_0556)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Population: Caucasian.
Doubling time: 22 hours (PubMed=9842975); 40 hours (PubMed=25984343); 26-36 hours (PubMed=30188626); ~28 hours (PBCF).
Karyotypic information: Hyperpentaploid karyotype. Has almost twice as many chromosomes as its parental cell line (T98) (PubMed=222778).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: HLA class I peptidome analysis by proteomics.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Brain; UBERON=UBERON_0000955.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975).
  • Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942).
  • Mutation; HGNC; 16051; PARD3; Unexplicit; Ex3-20del; Zygosity=Homozygous (PubMed=20215515).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Leu42Arg (c.125T>G); Zygosity=Unspecified (PubMed=9090379; PubMed=10560660; PubMed=28464039).
  • Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (PubMed=10416987; PubMed=14614447).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*02:01,02:01
HLA-BB*35:03,39:06
HLA-CC*04:01,07:02

Source: PubMed=27412690
Class I
HLA-AA*02:01:01
HLA-BB*36:06:02
HLA-CC*07:02:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.56
Native American0.16
East Asian, North4.73
East Asian, South0
South Asian6.52
European, North26.22
European, South60.81
Disease Glioblastoma (NCIt: C3058)
Glioblastoma (ORDO: Orphanet_360)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_B368 (T98)
Children:
CVCL_E1CJ (Ubigene T98G MCOLN1 KO)CVCL_E1CK (Ubigene T98G TPCN2 KO)
Sex of cell Male
Age at sampling 61Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-1690; COG; Cosmic-CLP=687586; ECACC=92090213; JCRB=IFO50303; JCRB=JCRB9041; KCLB=21690; PubMed=22570425; PubMed=25877200; RCB=RCB1954; Technion Genomics Center; TKG=TKG 0471

Markers:
AmelogeninX,Y
CSF1PO10,12
D1S165614,17
D2S44111
D2S133819,24
D3S135816
D5S81810,12
D7S8209,10
D8S117913,14
D10S124814
D12S39117,18
D13S31713
D16S53913
D18S5113,16
D19S43312,13
D21S1128,32.2
D22S104515,16
DYS3919
FGA21 (PubMed=22570425; PubMed=25877200)
21,22 (ATCC=CRL-1690; COG; KCLB=21690; Technion Genomics Center)
Penta D10,11
Penta E16
TH017,9.3
TPOX8
vWA17,20

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/T98G
https://www.synapse.org/#!Synapse:syn31544555
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-574.html
Publications

PubMed=222778; DOI=10.1002/jcp.1040990107
Stein G.H.
T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro.
J. Cell. Physiol. 99:43-54(1979)

PubMed=3413074; DOI=10.1073/pnas.85.16.6042; PMCID=PMC281901
Pereira-Smith O.M., Smith J.R.
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988)

PubMed=9090379; DOI=10.1038/ng0497-356
Steck P.A., Pershouse M.A., Jasser S.A., Yung W.-K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat. Genet. 15:356-362(1997)

PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-z
Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J.
Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.
Int. J. Cancer 79:640-644(1998)

DOI=10.1007/0-306-46861-1_11
Ali-Osman F.
Brain tumors.
(In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York; USA (1999)

PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x; PMCID=PMC8098486
Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C., Van Meir E.G.
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Brain Pathol. 9:469-479(1999)

PubMed=10560660; DOI=10.1097/00005072-199911000-00007
Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L., Collins V.P.
Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
J. Neuropathol. Exp. Neurol. 58:1170-1183(1999)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=14614447; DOI=10.1038/sj.onc.1207198
Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.
Oncogene 22:8233-8245(2003)

PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x; PMCID=PMC8095903
Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
Brain Pathol. 13:482-494(2003)

PubMed=14961077; DOI=10.1038/sj.onc.1207244
Wang Y.-L., Zhu S.-J., Cloughesy T.F., Liau L.M., Mischel P.S.
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Oncogene 23:1283-1290(2004)

PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x; PMCID=PMC11159392
Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T., Aoyagi M., Ohno K., Imoto I., Inazawa J.
Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.
Cancer Sci. 96:676-683(2005)

PubMed=17595512; DOI=10.1159/000104150
Rieger J., Frank B., Weller M., Wick W.
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Cell. Physiol. Biochem. 20:23-34(2007)

PubMed=18445040; DOI=10.1111/j.1742-4658.2008.06452.x
Kikuchi Y., Kakeya T., Nakajima O., Sakai A., Ikeda K., Yamaguchi N., Yamazaki T., Tanamoto K.-i., Matsuda H., Sawada J.-i., Takatori K.
Hypoxia induces expression of a GPI-anchorless splice variant of the prion protein.
FEBS J. 275:2965-2976(2008)

PubMed=19435942; DOI=10.1215/15228517-2009-025; PMCID=PMC2743214
Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T.W., Collins V.P.
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Neuro-oncol. 11:341-347(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20587068; DOI=10.1186/1471-2407-10-339; PMCID=PMC2909207
Nakabayashi H., Yawata T., Shimizu K.
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.
BMC Cancer 10:339.1-339.9(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22570425; DOI=10.1093/neuonc/nos072; PMCID=PMC3367844
Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K., Hamou M.-F., Delorenzi M., Hegi M.E.
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Neuro-oncol. 14:701-711(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26496030; DOI=10.18632/oncotarget.6171; PMCID=PMC4791243
Patil V., Pal J., Somasundaram K.
Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.
Oncotarget 6:43452-43471(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27412690; DOI=10.1074/mcp.M116.060350; PMCID=PMC5013317
Shraibman B., Kadosh D.M., Barnea E., Admon A.
Human leukocyte antigen (HLA) peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy.
Mol. Cell. Proteomics 15:3058-3070(2016)

PubMed=30188626; DOI=10.1134/S1990519X16050072
Kiseleva L.N., Kartashev A.V., Vartanyan N.L., Pinevich A.A., Samoylovich M.P.
Characteristics of A172 and T98G cell lines.
Tsitologiia 58:349-355(2016)

PubMed=28464039; DOI=10.1371/journal.pone.0176683; PMCID=PMC5413031
Hill V.K., Kim J.-S., James C.D., Waldman T.
Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.
PLoS ONE 12:E0176683-E0176683(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=33385022; DOI=10.1016/j.dib.2020.106643; PMCID=PMC7772531
de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G., Silva W.A., Valente V.
RNA sequencing data of different grade astrocytoma cell lines.
Data Brief 34:106643.1-106643.13(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-1690
BCRJ; 0406
CLS; 305030
ECACC; 92090213
IZSLER; BS TCL 63
JCRB; IFO50303
JCRB; JCRB9041
KCLB; 21690
RCB; RCB1954
TKG; TKG 0471
Cell line databases/resources CLO; CLO_0009236
CLO; CLO_0009258
CLO; CLO_0050636
MCCL; MCC:0000457
CLDB; cl4478
CLDB; cl4480
CLDB; cl4481
CLDB; cl4482
cancercelllines; CVCL_0556
Cell_Model_Passport; SIDM01171
CGH-DB; 154-1
Cosmic-CLP; 687586
DepMap; ACH-000571
LINCS_LDP; LCL-1357
Anatomy/cell type resources BTO; BTO:0001583
Biological sample resources BioSample; SAMN01821603
BioSample; SAMN01821719
BioSample; SAMN01821740
BioSample; SAMN03473051
BioSample; SAMN05292443
BioSample; SAMN07710005
BioSample; SAMN07710006
BioSample; SAMN07710007
BioSample; SAMN07710008
BioSample; SAMN07710009
BioSample; SAMN07710010
BioSample; SAMN07710011
BioSample; SAMN10988244
CRISP screens repositories BioGRID_ORCS_Cell_line; 357
Chemistry resources ChEMBL-Cells; CHEMBL3307777
ChEMBL-Targets; CHEMBL614775
GDSC; 687586
PharmacoDB; T98G_1562_2019
PubChem_Cell_line; CVCL_0556
Encyclopedic resources Wikidata; Q52609889
Experimental variables resources EFO; EFO_0002085
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM326205
GEO; GSM887687
GEO; GSM888779
GEO; GSM1374954
GEO; GSM1638664
GEO; GSM1638665
GEO; GSM1638666
GEO; GSM1670523
GEO; GSM2113432
GEO; GSM2113433
GEO; GSM2113434
GEO; GSM2113435
Polymorphism and mutation databases Cosmic; 687586
Cosmic; 759898
Cosmic; 849847
Cosmic; 850740
Cosmic; 897444
Cosmic; 1175821
Cosmic; 1217675
Cosmic; 1294953
Cosmic; 1610748
Cosmic; 1746960
Cosmic; 2302325
Cosmic; 2367552
Cosmic; 2491103
Cosmic; 2516040
Cosmic; 2701088
Cosmic; 2731176
Cosmic; 2732519
IARC_TP53; 2574
LiGeA; CCLE_712
Progenetix; CVCL_0556
Proteomic databases PRIDE; PXD000589
PRIDE; PXD002192
PRIDE; PXD003790
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number43